Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma

NCT05013268 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Cervical Squamous Cell Carcinoma

Interventions

DRUG: Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin

Sponsor

Ruijin Hospital